21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology

21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant... Breast Cancer Res Treat (2018) 168:69–77 https://doi.org/10.1007/s10549-017-4550-8 CLINICAL TRIAL 21‑Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B‑28/NRG Oncology 1,2 3 1,4 5 3 Eleftherios P. Mamounas  · Gong Tang  · Soonmyung Paik  · Frederick L. Baehner  · Qing Liu  · 3 1 5 5 5 5 Jong‑Hyeon Jeong  · S. Rim Kim  · Steven M. Butler  · Farid Jamshidian  · Diana B. Cherbavaz  · Amy P. Sing  · 5 1,6 1 1,6 3 Steven Shak  · Thomas B. Julian  · Barry C. Lembersky  · D. Lawrence Wickerham  · Joseph P. Costantino  · 1,6 Norman Wolmark   Received: 16 October 2017 / Accepted: 24 October 2017 / Published online: 11 November 2017 © Springer Science+Business Media, LLC 2017 Abstract ER-positive, tamoxifen-treated patients with RS assessment. Background The 21-gene recurrence score (RS) predicts Median follow-up time was 11.2 years. outcome and benefit from adjuvant chemotherapy benefit in Results In univariate analyses, RS was a significant predic - breast cancer patients treated with adjuvant endocrine ther- tor of outcome. In multivariate analyses, RS remained a sig- apy. In the NSABP B-28 study, we evaluated the 21-gene nificant independent predictor of outcome beyond clinico- RS for its prognostic impact and its ability to predict ben- pathologic factors, age, and type of surgery (p < 0.001). In efit from paclitaxel (P) in node-positive, estrogen receptor- the study population http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Breast Cancer Research and Treatment Springer Journals

21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology

Loading next page...
 
/lp/springer_journal/21-gene-recurrence-score-for-prognosis-and-prediction-of-taxane-rKz2eNvtpS
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Oncology
ISSN
0167-6806
eISSN
1573-7217
D.O.I.
10.1007/s10549-017-4550-8
Publisher site
See Article on Publisher Site

Abstract

Breast Cancer Res Treat (2018) 168:69–77 https://doi.org/10.1007/s10549-017-4550-8 CLINICAL TRIAL 21‑Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B‑28/NRG Oncology 1,2 3 1,4 5 3 Eleftherios P. Mamounas  · Gong Tang  · Soonmyung Paik  · Frederick L. Baehner  · Qing Liu  · 3 1 5 5 5 5 Jong‑Hyeon Jeong  · S. Rim Kim  · Steven M. Butler  · Farid Jamshidian  · Diana B. Cherbavaz  · Amy P. Sing  · 5 1,6 1 1,6 3 Steven Shak  · Thomas B. Julian  · Barry C. Lembersky  · D. Lawrence Wickerham  · Joseph P. Costantino  · 1,6 Norman Wolmark   Received: 16 October 2017 / Accepted: 24 October 2017 / Published online: 11 November 2017 © Springer Science+Business Media, LLC 2017 Abstract ER-positive, tamoxifen-treated patients with RS assessment. Background The 21-gene recurrence score (RS) predicts Median follow-up time was 11.2 years. outcome and benefit from adjuvant chemotherapy benefit in Results In univariate analyses, RS was a significant predic - breast cancer patients treated with adjuvant endocrine ther- tor of outcome. In multivariate analyses, RS remained a sig- apy. In the NSABP B-28 study, we evaluated the 21-gene nificant independent predictor of outcome beyond clinico- RS for its prognostic impact and its ability to predict ben- pathologic factors, age, and type of surgery (p < 0.001). In efit from paclitaxel (P) in node-positive, estrogen receptor- the study population

Journal

Breast Cancer Research and TreatmentSpringer Journals

Published: Nov 11, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from Google Scholar, PubMed
Create lists to organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off